Advertisement

Plötzlicher Herztod: Prognose der antiarrhythmischen Langzeittherapie

  • M. Manz
  • G. Steinbeck
  • B. Lüderitz
Conference paper

Zusammenfassung

Nach der Todesursachenstatistik der Bundesrepublik des Jahres 1979 zeigt die Zahl der an Krankheiten des Herz-Kreislauf-Systems Verstorbenen einen Anstieg von 39% auf 49% in den vergangenen 20 Jahren. Dieser Anstieg der Kreislauftoten ist auf eine Zunahme der ischämischen Herzkrankheit von 22% auf 35% in demselben Zeitraum zurückzuführen (Todesursachenstatistik DMW 1981). Untersuchungen von Lovegrove u. Thompson (1978) ergaben, daß ca. 71% dieser Personen innerhalb von 30 min nach Einsetzen von Symptomen versterben, d. h. sie erleiden einen sog. plötzlichen Tod. In 87% der innerhalb 1 h Verstorbenen konnte eine Rhythmusstörung des Herzens als unmittelbare Todesursache wahrscheinlich gemacht werden (Aspirin Myocardial Infarction Study Research Group 1980). In diesen Fällen wird der Tod durch eine prinzipiell überbrückbare elektrische Instabilität des Herzens herbeigeführt, nicht jedoch durch einen Endzustand eines Organversagens. Die wissenschaftlichen Bemühungen richteten sich deshalb auf die Erkennung von Patientengruppen, die vom plötzlichen Herztod bedroht sind, sowie auf die Entwicklung von Behandlungskonzepten zur Verhinderung dieser Todesfälle.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. A multicentre international study (1975) Improvement in prognogis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. Br Med J 3: 735–40CrossRefGoogle Scholar
  2. Anderson KP, DeCamilla J, Moss AJ (1978) Clinical significance of ventricular tachycardia (3 beats or longer) detected during ambulatory monitoring after myocardial infarction. Circulation 57: 890–896PubMedGoogle Scholar
  3. Andersen MP, Bechsgaard P, Frederiksen J, Hansen DA, Jurgensen H J, Nielsen B, Pedersen F, Pedersen-Bjergaard O/Rasmussen SL (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 27: 865–867CrossRefGoogle Scholar
  4. Armbrust CA, Levine SA (1950) Paroxysmal ventricular tachycardia: A study of one hundred and seven cases. Circulation 1: 28–40PubMedGoogle Scholar
  5. Aspirin Myocardial Infarction Study Research Group (1980) A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243: 661–669CrossRefGoogle Scholar
  6. Baber NS, Wainwright Evans D, Howitt G, Thomas M, Wilson C, Lewis JA, Dawes PM, Handler K, Tuson R (1980) Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yogoslavia. Br Heart J 44:96–100PubMedCrossRefGoogle Scholar
  7. Betablocker heart attack study group (1981) The betablocker heart attack trial. JAMA 246: 2073–2074CrossRefGoogle Scholar
  8. Cats VM, Lie KI, Van Capelle FJL, Durrer D (1979) Limitations of 24-hour ambulatory electrocardiographic recording in predicting coronary events after acute myocardial infarction. Am J Cardiol 44:1257–1262PubMedCrossRefGoogle Scholar
  9. Chamberlain DA, Julian DG, Boyle DMcC, Jewitt DE, Campbell RWF, Shanks RG, and others (1980) Oral mexiletine in high-risk patients after myocardial infarction. Lancet 20/27: 1324–1327CrossRefGoogle Scholar
  10. Chiang BN, Perlam LV, Ostrander LD, Epstein FH (1969) Relationship of premature systoles to coronary heart disease and sudden death in the Tecumseh epidemiologic study. Ann Intern Med 70:1159–1166PubMedGoogle Scholar
  11. Collaborative Group (1971) Phenytoin after recovery from myocardial infarction. Lancet 2: 1055–1057Google Scholar
  12. Davis HT, DeCamilla J, Bayer LW, Moss AJ (1979) Survivorship patterns in the posthospital phase of myocardial infarction. Circulation 60:1252–1258PubMedGoogle Scholar
  13. Hammermeister KE, DeRouen TA, Dodge HT (1979) Variables predictive of survival in patients with coronary disease. Circulation 59:421–430PubMedGoogle Scholar
  14. Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP (1981) Amiodarone: Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305: 539–545PubMedCrossRefGoogle Scholar
  15. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial. Lancet 17: 823–827CrossRefGoogle Scholar
  16. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AM (1978) Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimes. Circulation 58: 987–997Google Scholar
  17. Kannel WB, Sorlie P, McNamara PM (1979) Prognosis after initial myocardial infarction: The Framingham Study. Am J Cardiol 44: 53–59PubMedCrossRefGoogle Scholar
  18. Kaski JC, Girotti L, Messuti H, Rutitzky B, Rosenbaum MB (1981) Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64: 273–279PubMedCrossRefGoogle Scholar
  19. Kosowsky BD, Taylor J, Lown B, Ritchie RF (1971) Long-term use of procainamide following acute myocardial infarction. Circulation 47:1204–1210Google Scholar
  20. Kotler MN, Tabatznik B, Mower MM, Tominaga S (1973) Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation 47: 959–966PubMedGoogle Scholar
  21. Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR (1974) Prehospital ventricular defibrillation. N Engl J Med 291: 317–321PubMedCrossRefGoogle Scholar
  22. Lovegrove T, Thompson P (1978) The role of acute myocardial infarction in sudden cardiac death — a statisticians nightmare. Am Heart J 96: 711–713PubMedCrossRefGoogle Scholar
  23. Mason JW, Winkle RA (1980) Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 303:1073–1077PubMedCrossRefGoogle Scholar
  24. Moss AJ, Davis HT, DeCamilla J, Bayer LW (1979) Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 60:998–1003PubMedGoogle Scholar
  25. Myerburg RJ, Conde C, Sheps DS, Appel RA, Kiem I, Sung RJ, Castellanos A (1979) Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: Comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest. Circulation 59: 855–863PubMedGoogle Scholar
  26. Nielsen BL, Nielsen JC, Nielsen JS (1978) Can procainamide improve the prognosis of patients with ventricular arrhythmias after myocardial infarction? Dan Med Bull 25:121–125PubMedGoogle Scholar
  27. Paul O, Schatz M (1971) On sudden death. Circulation 43: 7–10PubMedGoogle Scholar
  28. Peter T, Ross D, Duffield A, Luxton M, Harper R, Hunt D, Sloman G (1978) Effect on survival after myocardial infarction of long-term treatment with phenytoin. Br Heart J 40:1356–1360PubMedCrossRefGoogle Scholar
  29. Report of the Joint International Society and Federation of Cardiology World Health Organization Task Force on Standardization of Clinical Nomenclature (1979) Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59: 607–609Google Scholar
  30. Ruberman W, Weinblatt E, Goldberg GD, Frank CW, Shapiro S (1977) Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 297: 750–759PubMedCrossRefGoogle Scholar
  31. Ruskin JN, DiMarco JP, Garan H (1980) Out-of-hospital cardiac arrest: Electrophysiologic observations and selection of longterm antiarrhythmic therapy. N Engl J Med 303: 607–613PubMedCrossRefGoogle Scholar
  32. Schaffer WA, Cobb LA (1975) Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 293: 259–262PubMedCrossRefGoogle Scholar
  33. Schulze RA, Strauss HW, Pitt B (1977) Sudden death in the year following myocardial infarction. Am J Med 62:192–199PubMedCrossRefGoogle Scholar
  34. Temple R, Pledger GW (1980) The FDA’s critique of the anturane reinfarction trial. N Engl J Med 303:1488–1492PubMedCrossRefGoogle Scholar
  35. The Norwegian multicenter study group (1981) Timolol-induced reduction in mortality and re-infarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807CrossRefGoogle Scholar
  36. Todesursachenstatistik (Cause-of-death statistics) (1981) Dtsch Med Wochenschr 106:157–158Google Scholar
  37. Van Durme JP, Pannier RH (1976) Prognostic significance of ventricular dysrhythmias 1 year after myocardial infarction. Am J Cardiol 37:178CrossRefGoogle Scholar
  38. Van Durme JP, Bogaert MG (1980) Prevention of sudden death. The role of antiarrhythmic therapy. In: Kulbertus HE, Wellens HJJ (eds) Sudden death. Nyhoff, The Hague p 331Google Scholar
  39. Vismara LA, Amsterdam EA, Mason DT (1975) Relation of ventricular arrhythmias in the late hospital phase of acute myocardial infarction to sudden death after hospital discharge. Am J Med 59:6–12PubMedCrossRefGoogle Scholar
  40. Wellens HJJ, Bär FWHM, Vanagt EJDM, Brugada P (1982) Medical treatment of ventricular tachycardia: Considerations in the selection of patients for surgical treatment. Am J Cardiol 49: 186–193PubMedCrossRefGoogle Scholar
  41. Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werkö L (1974) Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet 2:1157–60PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • M. Manz
  • G. Steinbeck
  • B. Lüderitz

There are no affiliations available

Personalised recommendations